SCHEMBL1338257

SCHEMBL1338257

C#Cc1ccc2c(c1)c1cc(-c3ccc(Cl)cc3Cl)c(=O)n(C)c1n2C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ GABRG2 P18507 5/20 0.37
▸ GABRB3 P28472 5/20 0.37
▸ GABRA5 P31644 5/20 0.37
▸ GABRA1 P14867 4/20 0.37
▸ GABRA3 P34903 1/20 0.37
▸ GABRA2 P47869 1/20 0.37
▸ F2RL3 Q96RI0 1/20 0.36
▸ HSD11B1 P28845 3/20 0.35
▸ CNR1 P21554 3/20 0.33
▸ CNR2 P34972 3/20 0.33
▸ GSK3A P49840 2/20 0.33
▸ GSK3B P49841 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ RGS12 O14924 1/20 0.33
▸ GMNN O75496 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339422 0.89 KDM4E (0.39) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1339399 0.85 GABRA1 (0.41) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL2382190 0.83 F2RL3 (0.46) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1339317 0.82 KDM4E (0.42) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1338090 0.81 KDM4E (0.52) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL2385324 0.81 ALDH1A1 (0.47) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1339415 0.81 GABRA1 (0.41) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1339426 0.81 PTGER4 (0.47) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1336873 0.80 GABRA1 (0.42) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1339573 0.80 KDM4E (0.46) KDM4EALDH1A1GAAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 KDM4E 1908/4885ALDH1A1 283/4885GAA 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback